Floatz logo

Onabotulinum Toxin A

Neuralgia

Allan Vestergaard Danielsen, MDUNKNOWNPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
73/ 100

Competitive context

48 Active assets in the Neuralgia cohort.

Asset / SponsorPhaseRating
Dexmedetomidine
Universidad Juárez Autónoma de Tabasco
Phase 4BBB
Midazolam
Minia University
Phase 4BBB
Lidocaine
Ataturk University
Phase 4BBB
(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone
Margaux M. Salas, PhD
Phase 4BBB
Marcaine
Medipol University
Phase 4BBB

View all 50 →

Same molecule, other indications

Onabotulinum Toxin A is also rated in:

migraine disorderActive
BB
Indicative · Phase 4
66 / 100
View asset →
multiple sclerosisDormant
CCC
Indicative · Phase 4
51 / 100
View asset →
obesity disorderDormant
CC
Indicative · Phase 1/2
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →